Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …

Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Background Calcitonin gene-related peptide plays an important role in migraine
pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene …

Background The calcitonin gene-related peptide (CGRP) pathway is important in migraine
pathophysiology. We assessed the efficacy and safety of erenumab, a fully human …

Migraine is a highly disabling neurovascular disorder characterized by a severe headache
(associated with nausea, photophobia and/or phonophobia), and trigeminovascular system …

The calcitonin/CGRP family of peptides includes calcitonin, α and β CGRP, amylin,
adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist …

Background The calcitonin gene-related peptide (CGRP) pathway is a promising target for
preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG …

Objective–To briefly describe the history of and available data on anti‐calcitonin gene‐
related peptide (CGRP) therapies for headache. Background–CGRP was proposed as a …